Latest news with #CraigHettenbach
Yahoo
07-07-2025
- Business
- Yahoo
Morgan Stanley Maintains a Buy Rating on LifeStance Health (LFST), Keeps the PT at $10
LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the 13 Stocks Under $5 With High Upside Potential. On May 27, Morgan Stanley analyst Craig Hettenbach maintained a Buy rating on LifeStance Health Group, Inc. (NASDAQ:LFST), keeping the associated price target the same at $10. The analyst based the rating on the company's growth potential and strategic positioning, stating that LifeStance Health Group, Inc. (NASDAQ:LFST) is well-positioned to capitalize on the rising demand for outpatient mental health services. A close-up of a healthcare professional studying a computer screen with data while consulting with a patient. This trend is driven by reduced social stigma regarding seeking behavioral health care, along with a shift to in-network insurance coverage. According to the analyst, LifeStance Health Group, Inc. (NASDAQ:LFST) has a hybrid care model that mixes in-person and virtual visits, supporting this demand through increasing flexibility for both clinicians and patients. The analyst further reasoned that LifeStance Health Group, Inc. (NASDAQ:LFST) is focusing on long-term EBITDA margin expansion, and management is confident about its potential to attain 15%-20% margins, up from the current guidance of around 10% by 2025. Hettenbach expects various factors to drive this margin expansion, including center margins improvements, slower growth in general and administrative expenses relative to revenue, and the introduction of higher-margin services. LifeStance Health Group, Inc. (NASDAQ:LFST) provides outpatient mental health services, including psychological and neuropsychological testing, psychiatric evaluations and treatment, and individual, family, and group therapy. The company operates through a mental health platform and also offers virtual care via its online delivery platform, as well as in-person care at centers located in 32 US states. While we acknowledge the potential of LFST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
16-06-2025
- Business
- Yahoo
Morgan Stanley Raises Tenet Healthcare (THC) PT to $210, Keeps Overweight Rating
Tenet Healthcare Corporation (NYSE:THC) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, Morgan Stanley raised its price target on Tenet Healthcare to $210 from $175, while maintaining an Overweight rating on the shares. Analyst Craig Hettenbach highlighted Tenet Healthcare as Morgan Stanley's preferred stock within the hospital sector. Tenet Healthcare's net operating revenues in Q1 2o25 were $5.2 billion. The company's consolidated Adjusted EBITDA increased by 14% over Q1 2024 to $1.163 billion, with an Adjusted EBITDA Margin of 22.3%, which shows a 3.2% improvement over the prior year. USPI/United Surgical Partners International Adjusted EBITDA alone grew 16% year-over-year in Q1 to $456 million, while the same-facility revenues increased by 6.8%. A room full of medical personnel collaborating on a treatment plan for a patient. Tenet Healthcare plans to deploy $250 million annually for USPI acquisitions, with a focus on diversifying service lines like orthopedics. Despite the strong performance, Tenet Healthcare is not updating its full-year 2025 guidance due to the early stage of the year and potential uncertainties. Tenet Healthcare Corporation (NYSE:THC) is a diversified healthcare services company in the US. The company operates through 2 segments: Hospital Operations & Services, and Ambulatory Care. While we acknowledge the potential of THC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
16-06-2025
- Business
- Yahoo
Morgan Stanley Upgrades HCA Healthcare (HCA) PT to $410, Keeps Equal Weight Rating
HCA Healthcare Inc. (NYSE:HCA) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, Morgan Stanley analyst Craig Hettenbach increased the price target for HCA Healthcare to $410 from $355, while maintaining an Equal Weight rating on the shares. Hettenbach attributes HCA's consistently strong margins to its scale and effective operating initiatives. In Q1 2025, HCA Healthcare experienced broad-based volume growth, with inpatient admissions up 2.6% year-over-year, equivalent admissions increasing by 2.8%, and emergency room visits rising by 4%. Same facility revenue grew by ~6% year-over-year, with revenue per equivalent admission increasing by ~3%. The company also reported diluted EPS of $6.45, which was up over 20% year-over-year. A team of healthcare professionals in lab coats and masks meeting at a hospital ward. HCA Healthcare expanded its network in the quarter and increased its facilities/sites of care by 3.3% to ~2,750, and its inpatient bed capacity by about 2%. Inpatient occupancy in Q1 was 77%, which was higher than 75% last year. HCA Healthcare also spent $227 million on acquisitions, which included Catholic Medical Center and Lehigh Medical Center. The company received $161 million from asset sales, primarily from the sale of Regional Medical Center of San Jose. HCA Healthcare Inc. (NYSE:HCA) owns and operates hospitals and related healthcare entities in the US. It operates general and acute care hospitals that offer medical and surgical services, such as inpatient care and outpatient services. While we acknowledge the potential of HCA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Globe and Mail
24-05-2025
- Business
- Globe and Mail
‘Time to Choose Sides on HIMS Stock' as Analysts Assign Mixed Ratings
Hims & Hers Health (HIMS) has received mixed ratings from Top Wall Street analysts, with Morgan Stanley (MS) maintaining a Hold rating while Citi (C) reiterates a Sell rating. The company's strong app growth and steady revenue expansion contrast with pricing issues and tough competition, leading to divided opinions on its prospects. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter HIMS is a direct-to-consumer telehealth company that offers treatments for hair loss, mental health, and weight management through its digital platform. Morgan Stanley Analyst Highlights Growth Morgan Stanley analyst Craig Hettenbach kept a Hold rating with a $40 price target, citing steady app downloads and sales growth. He highlighted that app downloads surged 25% year-over-year in April, and cumulative downloads hit 5.2 million, which shows continued user adoption. However, according to Second Measure, observed sales data suggest 67% QTD year-over-year growth in Q2, slightly below the 71% guidance midpoint, with weekly growth dipping to its lowest level since last November. The analyst noted HIMS is expanding, but fluctuations in app downloads and sales could pose short-term hurdles. Citi Cites Pricing Pressures for HIMS Stock Citi analyst Daniel Grosslight maintained a Sell rating with a $30 price target, pointing to pricing challenges in the weight-loss drug market. The analyst noted that NovoCare, Ro, and LifeMD have adjusted their pricing. Thus, he raised concerns that Hims may lose customers to rivals offering more affordable options, making it harder to sustain growth at current pricing levels. Is HIMS Stock a Good Buy? Turning to Wall Street, HIMS stock has a Hold consensus rating based on four Buys, eight Holds, and two Sells assigned in the last three months. At $45.50, the average Hims & Hers stock price target implies a 14.99% upside potential. See more HIMS analyst ratings
